Dr Jutta Marfurt
Senior research fellow
PhD (Epidemiology), Master of Science (Epidemiology), University of Basel, 2006; Master of Science (Control of Infectious Diseases), University of London, 2002; Postgraduate diploma (Infectious Diseases), University of London, 2000; Bachelor of Science (Medical Parasitology), University of Basel, 1990.
Approved level of HDR supervision at Charles Darwin University:
Principal Supervisor for PhD
Jutta is a molecular parasitologist with postgraduate qualifications in epidemiology and public health, with an adjunct academic appointment at Charles Darwin University.
Jutta’s main interests are the development and validation of novel tools and strategies to improve diagnosis and surveillance of infectious diseases. Jutta’s previous expertise includes the development and validation of novel diagnostic tools for amoebiasis and leishmaniasis, the study of innate and adaptive immune mechanisms in autoimmune diseases and malaria, and the investigation of novel approaches for the monitoring of drug resistant Plasmodium falciparum malaria.
During the course of her career she has gained extensive technical and field work experience in Tanzania, Papua New Guinea and Indonesia, becoming an expert in ex vivo characterisation and molecular studies of drug resistant Plasmodium species.
Jutta is committed to undertake research in the field of malaria biology with the goal of enhancing the scientific understanding of drug resistant malaria. Current research activities focus on facilitating the development and optimisation of novel tools for the monitoring of parasite resistance that will ultimately inform the decision on anti-malarial treatment policy.
- ACROSS Study: Populations at risk of malaria and drug induced haemolysis
- Phenotypic characterisation of chloroquine resistance in Plasmodia
- Ex vivo drug susceptibility testing of novel anti-malarial compounds in drug resistant clinical field isolates of P. falciparum and P. vivax
- A genome-wide scan for chloroquine resistance markers in Plasmodium vivax.
- Nilsen, A., LaCrue, A. N., White, K. L., Forquer, I. P., Cross, R. M., Marfurt, J., et al. (2013). Quinolone-3-diarylethers: A new class of antimalarial drug. Science Translational Medicine, 5(177).
- Auburn, S., Marfurt, J., Maslen, G., Campino, S., Ruano Rubio, V., Manske, M., et al. (2013). Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing. PLoS ONE, 8(1).
- Price, R. N., Auburn, S., Marfurt, J., & Cheng, Q. (2012). Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends in Parasitology, 28(11), 522-529.
- Marfurt, J., Chalfein, F., Prayoga, P., Wabiser, F., Wirjanata, G., Sebayang, B., et al. (2012). Comparative ex vivo activity of novel endoperoxides in multidrug-resistant Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 56(10), 5258-5263.
- Marfurt, J., Chalfein, F., Prayoga, P., Wabiser, F., Kenangalem, E., Piera, K. A., et al. (2011). Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 55(9), 4461-4464.
- Marfurt, J., Chalfein, F., Prayoga, P., Wabiser, F., Kenangalem, E., Piera, K. A., et al. (2011). Ex Vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 55(3), 961-966.
- Marfurt, J., Smith, T. A., Hastings, I. M., Muller, I., Sie, A., Oa, O., et al. (2010). Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: Evaluation of a community-based approach for the molecular monitoring of resistance. Malaria Journal, 9(1).
- Marfurt, J., De Monbrison, F., Brega, S., Barbollat, L., Muller, I., Sie, A., et al. (2008). Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: Mutations in pvdhfr and pvmdr1. Journal of Infectious Diseases, 198(3), 409-417.
- Marfurt J, Müller I, Sie A, Oa O, Reeder JC, Smith TA, et. al. (2008). The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malaria Journal, 7(4).
- Marfurt, J., Muller, I., Sie, A., Maku, P., Goroti, M., Reeder, J. C., et al. (2007). Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 77(5), 947-954.